Treatments reported in three or more studies (excluding IRT and antibiotics)a
| Treatment type . | Median percentage of patients (range) . | No. of publications . |
|---|---|---|
| Steroids | 56.4 (32.9–85.7) | 9 |
| Rituximab | 12.2 (5.5–34.8) | 7 |
| Mycophenolate | 7.4 (1.8–13.2) | 6 |
| Azathioprine | 7.0 (3.6–28.6) | 8 |
| Antimalarials | 4.4 (2.6–7.3) | 4 |
| TNF-α inhibitors | 3.7 (1.5–9.0) | 5 |
| Methotrexate | 3.6 (0.8–15.4) | 5 |
| Tacrolimus | 3.0 (2.6–3.0) | 3 |
| Cyclophosphamide | 2.6 (0.4–10.9) | 3 |
| Abatacept | 2.4 (0.4–3.0) | 4 |
| Sirolimus | 2.0 (0.8–7.5) | 4 |
| Cyclosporine | 1.7 (0.8–2.2) | 4 |
| Treatment type . | Median percentage of patients (range) . | No. of publications . |
|---|---|---|
| Steroids | 56.4 (32.9–85.7) | 9 |
| Rituximab | 12.2 (5.5–34.8) | 7 |
| Mycophenolate | 7.4 (1.8–13.2) | 6 |
| Azathioprine | 7.0 (3.6–28.6) | 8 |
| Antimalarials | 4.4 (2.6–7.3) | 4 |
| TNF-α inhibitors | 3.7 (1.5–9.0) | 5 |
| Methotrexate | 3.6 (0.8–15.4) | 5 |
| Tacrolimus | 3.0 (2.6–3.0) | 3 |
| Cyclophosphamide | 2.6 (0.4–10.9) | 3 |
| Abatacept | 2.4 (0.4–3.0) | 4 |
| Sirolimus | 2.0 (0.8–7.5) | 4 |
| Cyclosporine | 1.7 (0.8–2.2) | 4 |
TNF-α, tumor necrosis factor alpha.
Six case studies reporting monotherapies were excluded, as all patients were administered the same treatment.